Living Longer and Better: Health-Related Quality of Life  by de Quadros, Alexandre Schaan
Rev Bras Cardiol Invasiva. 
2013;21(1):5-6
© 2013 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. All rights reserved.
Editorial
Living Longer and Better: Health-Related  
Quality of Life
Alexandre Schaan de Quadros
I n cardiology and medicine in general, doctors and health professionals usually focus on increasing patient survival. However, for many individuals, quality of 
life is a more important factor than how lifespan. Thus, 
the concept of health-related quality of life (HRQoL) 
emerges, and one of the aspects included in what is 
called health status, or the variation of the impact that 
disease has on the life of an individual, as expressed by 
him/herself.1 Health status can be assessed, as shown in 
Figure 1, by symptom manifestation, physical limitation, 
and quality of life.
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In Brazil, relatively few studies have addressed 
this important issue. Recently, our group evaluated the 
HRQoL in patients with stable coronary syndromes 
through the Seattle Angina Questionnaire, identifying 
predictors of improvement and their distribution in a 
local population of patients undergoing percutaneous 
coronary intervention.2 In other studies, patients with 
unstable coronary syndromes were evaluated using the 
same tool, which has been validated for the Brazilian 
population.3,4
Some specific studies that analysed HRQoL in 
hypertensive patients have been performed in Brazil.5,6 
In general, they identified an important negative impact 
of hypertension on HRQoL.
In this issue of the Revista Brasileira de Cardiolo-
gia Invasiva (Brazilian Journal of Invasive Cardiology) 
Armaganijan et al.7 report their pioneering experience 
in the effect of percutaneous renal denervation in the 
quality of life in patients with chronic hypertension. 
Evaluating ten patients through the EuroQol tool, it 
was observed that the magnitude of blood pressure 
reduction was not associated with better HRQoL, but 
those who experienced a reduction in the number of 
antihypertensive drugs reported better health status. The 
authors suggest that the renal sympathetic denervation 
may be a promising adjunct strategy in the treatment 
of systemic hypertension, and further studies with larger 
numbers of patients are needed to confirm these results.
The report by Armaganijan et al.7 is a further step 
both in the study of HRQoL and the performance of 
renal artery denervation in patients with drug-resistant 
systemic hypertension in our country. The authors should 
be congratulated for their initiative in both areas, and 
certainly further analysis should be undertaken to explore 
and clarify pending issues. Some limitations of the study, 
such as the sample size, were adequately addressed 
by the authors. Another important aspect is the device 
used for the renal denervation.7 This information is not 
available in the manuscript, but it is relevant for the 
interpretation of the results, as the analysis of a treat-
ment effect on HRQoL cannot be separated from how 
it is performed and its clinical outcomes.
The main studies that demonstrated the benefits 
of the renal denervation procedure to control drug-
resistant hypertension used catheters dedicated to this 
purpose.8 Some authors have suggested that cardiac 
ablation catheters could also be used for renal de-
nervation procedures.9 However, these catheters have 
been developed to produce lesions in the ventricular 
myocardium, and the renal ablation catheter validated 
in the Symplicity Trial uses significantly lower power 
than that employed in cardiac ablation procedures. 
Although it is possible to adjust the power of use, 
it remains unknown whether the positive results 
with catheters used in the Symplicity Trial can be 
extrapolated to procedures with cardiac ablation 
catheters.10 The latter may result in better, equivalent, 
or worse outcomes than the catheters that have 
already been validated; this answer can only be 
achieved through randomized clinical trials with 
an adequate numbers of patients.
Doctor. Professor at the Post-Graduation Course in Cardiology Instituto 
de Cardiologia/Fundação Universitária de Cardiologia. Porto Alegre, 
RS, Brazil.
Correspondence to: Alexandre Schaan de Quadros. Serviço de Hemodi-
nâmica – Instituto de Cardiologia/Fundação Universitária de Cardiologia. 
Av. Princesa Isabel, 395 – Porto Alegre, RS, Brazil – CEP 90620-000
E-mail: alesq@terra.com.br
Received on: 3/10/2013 • Accepted on: 3/11/2013
Quadros 
Health-Related Quality of Life
Rev Bras Cardiol Invasiva. 
2013;21(1):5-6
6
In conclusion, renal denervation in patients with 
refractory systemic arterial hypertension has generated 
great interest in the interventional and cardiology com-
munities, due to the treatment potential of a condition 
that is highly prevalent and associated with significant 
morbidity and mortality. HRQoL assessment is certainly 
one of the key aspects of the evaluation of this new 
technology, and many studies evaluating this question are 
forthcoming. The responses regarding the effectiveness of 
renal denervation in the long-term control of systemic 
hypertension, durability, and the effect on cardiovascular 
complications and HRQoL will soon emerge with the 
results of the Symplicity 3 Trial and others.
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Figure – Functional status and health-related quality of life in a model of coronary artery disease (CAD).
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